Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid

Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid

In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.

Scope

*Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types

*Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions

*Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types

*Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights

A low level of interest from drug developers means unmet needs in the SCLC, mesothelioma, primary brain and thyroid cancer markets are likely to remain unfulfilled. Drug developers should realize that despite being low-incidence tumor types, high unmet needs could result in significant financial rewards and a foothold in the market to build upon.

Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono) shows the most promise in the current NSCLC pipeline. Recent clinical trial results mean Erbitux may become a viable option in the first-line treatment of NSCLC, particularly for those patients ineligible for Avastin (bevacizumab; Genentech/Roche) therapy.

Vectibix (panitumumab; Amgen) and zalutumumab (HuMax-EGFR; Genmab/Medarex) show great promise to compete with Erbitux in the head and neck cancer market, particularly due to potential toxicity advantages that fully human monoclonal antibodies may have.

Reasons to Purchase

*Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment

*Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction

*Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

22-Jul-08 Format: PDF & SlidePack Pages: 328

Table of Contents
Price: $11,400.00 / €7,619.76

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions